Peer Review History

Original SubmissionNovember 30, 2020
Decision Letter - Muhammad Adrish, Editor

PONE-D-20-37556

Clinical Manifestations, Associated Risk Factors and Treatment Outcomes of Chronic Pulmonary Aspergillosis (CPA): An Experience from Tertiary Care Hospital in Lahore, Pakistan

PLOS ONE

Dear Dr. Akram,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please see comments made by the reviewers and provide point by point response in your revised manuscript. Manuscript will also benefit from expert native language editing prior to resubmission.

Please submit your revised manuscript by March 29th, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

  • The name of the colleague or the details of the professional service that edited your manuscript
  • A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
  • A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. Thank you for including your statement regarding patient consent from living patients. In your ethics statement in the manuscript and in the online submission form, please clarify whether any patients were unable to provide written informed consent regarding the use of the clinical records e.g. because they were deceased; if so, please state whether the IRB or ethics committee waived the requirement for informed consent from these patients.

4. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records/samples were accessed.

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a fairly straightforward retrospective study of outcomes in pulmonary aspergillosis. Overall it provides helpful granular information regarding risk of mortality and complications for various types of pulmonary aspergillosis and as such is of value to the literature.

Major comments:

1. There are many grammatical and spelling errors and the document would benefit from an edit by a native english speaker.

2. Mortality is discussed but I don't see any discussion of the average duration of follow up for cases. Mortality is 100% if the follow up period is long enough.

3. I don't know if it adds anything to say that longer LOS and ICU admission predict mortality as hospitalization and ICU admission tend to proceed mortality and are outcomes themselves.

Reviewer #2: The manuscript by Akram et al descibes clinical characteristics of a cohort of patients with pulmonary aspergillosis. The strenght of the study is the large number of patients with postTB aspergilloma. However, the topic has been extensively reviewed in the last years and the manuscript does not add information to current knowledge. The english academic language needs some corrections.

Reviewer #3: The study investigated the clinical manifestations, associated risk factors and treatment outcomes of chronic pulmonary aspergillosis in a tertiary care hospital in Pakistan. It’s important. However, there are several issues in the study.

1.The dosage and course of steroid, and respiratory complications (Table 4) were not clearly described in the study.

2.Age distribution, treatment choice, and the impact on prognosis in patients with tuberculosis is not well analyzed.

3.Moreover, many factors such as underlying conditions and treatment medications may also impact the alarming mortality rate. More detailed analysis is needed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Chao Wu

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer 1: I have incorporated all of your suggestions into my revision. They were helpful. Thank you.

Reviewer 2: I have incorporated all of your suggestions into my revision. They were helpful. Thank you.

Reviewer 3: I have incorporated all of your suggestions into my revision. They were helpful. Thank you.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Muhammad Adrish, Editor

PONE-D-20-37556R1

Clinical Manifestations, Associated Risk Factors and Treatment Outcomes of Chronic Pulmonary Aspergillosis (CPA): An Experience from Tertiary Care Hospital in Lahore, Pakistan

PLOS ONE

Dear Dr. Akram,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please review comments made by the reviewer and provide point by point response in your revised manuscript.. 

==============================

Please submit your revised manuscript by June 5th, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The manuscript has been greatly improved. The description of statistical analysis needs further clarification regarding the multiple regression analysis and how parameters were selected. In the tables it should be clarified whether range, IQR or SD is presented.

The are still a number of spelling errors.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Respected Editor,

We have received revision for our submitted manuscript. We have hereby addressed all the concerns of the reviewer and all the suggestions made by the reviewer have been duly acknowledged. We are hopeful that the concerns of the reviewer will be satisfied by revised version of the manuscript. We have attached point-by-point response to the concerns of the reviewer and the revised version of manuscript has been highlighted in order to make the changes evident. Please let us know if there are any other suggestions or if any further changes are required.

We are thankful to the editor and the reviewers for their time and efforts in putting their valuable suggestions and recommendations to make this manuscript more scientifically elegant and technically sound.

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: There is no retracted reference in our article. We did some changes to the reference list in the previous revision. Following are the new references that were added:

Number in References References Added

25. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70(3):270-7.

26. Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette C, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clinical Microbiology and Infection. 2005;11(6):427-9.

36. Uzunhan Y, Nunes H, Jeny F, Lacroix M, Brun S, Brillet P-Y, et al. Chronic pulmonary aspergillosis complicating sarcoidosis. European Respiratory Journal. 2017;49(6).

Apart from that, in this revision, a duplicated reference has been removed. The reference present at number 47 in the previous version, was also present at number 12. Below are the details of that particular reference:

Number in previous version. Reference Removed

47. Iqbal N, Irfan M, Zubairi ABS, Jabeen K, Awan S, Khan JA. Clinical manifestations and outcomes of pulmonary aspergillosis: experience from Pakistan. BMJ open respiratory research. 2016;3(1).

2. Please ensure that you refer to Table 4 in your text as, if accepted, production will need this reference to link the reader to the Table.

Response: The revised manuscript has followed the direction.

3. Please upload a copy of Supporting information Figure S1 which you refer to in your text on line 586.

Response: The revised manuscript has followed the direction.

Reviewer 2: Reviewer Comments

Reviewer: The manuscript has been greatly improved. The description of statistical analysis needs further clarification regarding the multiple regression analysis and how parameters were selected. In the tables it should be clarified whether range, IQR or SD is presented.Theere are still a number of spelling errors.

Response: Respected reviewer, we are pleased to know that you have seen great improvements in our revised manuscript. Your concern towards our manuscript is really appreciated and we are thankful that you are taking pains to recommend further improvements.

Concern 1: The description of statistical analysis needs further clarification regarding the multiple regression analysis and how parameters were selected.

Response 1: Respected reviewer, prior to performing the multivariate analysis, univariate analyses of the independent variables with the outcomes (that were stable/recovered, Deteriorated, and Mortality) were conducted. For the univariate analysis, all the parameters/variables that were clinically and biologically plausible, and all those indicated by previous literature, were selected. The variables reaching significance on univariate analyses, i.e., p ≤ 0.05, were selected for multinomial logistic regression analysis, in order to determine the independent factors associated with mortality. Furthermore, in regression output, the redundant parameters were excluded from the model. The results were presented in tables as p-value and odds ratio, along with 95% confidence intervals. For your convenience, we have highlighted the text in methodology, in which we have mentioned that how the variables were selected.

Concern 2: In the tables it should be clarified whether range, IQR or SD is presented.

Response 2: Respected reviewer, the mentioned aspect has been clarified and highlighted in tables.

Concern 3: Theere are still a number of spelling errors.

Response 3: Respected reviewer, all the spelling errors have been corrected and the manuscript has been subjected to a review by a native speaker. We expect that the revised version will satisfy this concern.

Respected reviewer,

We have tried our best to improve the manuscript and have made and highlighted the recommended changes in the manuscript. In this point-by-point response document, we did not list all the changes, but the changes are marked in the revised version. We are hopeful that this revision will meet with approval.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Muhammad Adrish, Editor

PONE-D-20-37556R2

Clinical Manifestations, Associated Risk Factors and Treatment Outcomes of Chronic Pulmonary Aspergillosis (CPA): An Experience from Tertiary Care Hospital in Lahore, Pakistan

PLOS ONE

Dear Dr. Khan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please review comments ​made by the reviewer and address them in your revised manuscript. Specifically language editing is required prior to acceptance of the manuscript.

==============================

Please submit your revised manuscript by August 14th, 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Explanation of the statistical analyses has greatly improved. The document is still somewhat difficult to read and it would benefit from a once over by a native english speaking editor, but I think the data and conclusions are sound.

Reviewer #2: The manuscript has been greatly improved. Comments have been addressed. However the academic language needs revision.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Brett Williams

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 3

Respected Editor,

We have received further revision for our submitted manuscript. The concerns of the reviewers have been duly acknowledged. We are hopeful that the concerns of the reviewers will be satisfied by this version of the manuscript. We have attached point-by-point response to the concerns of the reviewers and the revised version of manuscript has been highlighted in order to make the changes evident.

We are greatly thankful to the editor and the reviewers for their time and efforts in putting their valuable suggestions and recommendations to make this manuscript scientifically elegant, technically sound and comprehendible.

Reviewer Comments

Reviewer 1: Explanation of the statistical analyses has greatly improved. The document is still somewhat difficult to read and it would benefit from a once over by a native english speaking editor, but I think the data and conclusions are sound.

Response: Respected reviewer, we are pleased to know that you are satisfied with the explanation of statistical analyses. The manuscript has been subjected to review by a native English-speaking editor and Proofreading certificate is attached. We are hopeful that the revised version will satisfy this concern.

Respected reviewer,

We have tried our best to improve the manuscript by subjecting it to an extensive review by a native English speaking editor. We are hopeful that this revision will meet with approval.

Reviewer 2: The manuscript has been greatly improved. Comments have been addressed. However the academic language needs revision.

Response: Respected reviewer, we are pleased to know that you have seen great improvements in the manuscript. The manuscript has been subjected to review by a native English-speaking editor and Proofreading certificate is attached. We are hopeful that the revised version will satisfy this concern.

Respected reviewer,

We have tried our best to improve the manuscript by subjecting it to an extensive review by a native English-speaking editor. We are hopeful that this revision will meet with approval.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Muhammad Adrish, Editor

Clinical Manifestations, Associated Risk Factors and Treatment Outcomes of Chronic Pulmonary Aspergillosis (CPA): Experiences from a Tertiary Care Hospital in Lahore, Pakistan

PONE-D-20-37556R3

Dear Dr. Khan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Adrish, MD, MBA, FCCP, FCCM

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All comments have been addressed

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The manuscript has been greatly improved.

All relevant comments have been met.

The manuscript merits publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Formally Accepted
Acceptance Letter - Muhammad Adrish, Editor

PONE-D-20-37556R3

Clinical Manifestations, Associated Risk Factors and Treatment Outcomes of Chronic Pulmonary Aspergillosis (CPA): Experiences from a Tertiary Care Hospital in Lahore, Pakistan

Dear Dr. Khan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Muhammad Adrish

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .